What is the clinical evidence from this study?

Study design: Review. Population: Dilated Cardiomyopathy. Intervention: Immunoadsorption therapy.

What does this research mean for the field?

Specific antimyocardial autoantibodies directly contribute to the pathophysiology, arrhythmias, and myocardial damage in dilated cardiomyopathy, rather than acting merely as epiphenomena of myocyte injury. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

January 1, 2009Circulation JournalOpen Access

Autoimmune Mechanisms Underlying Dilated Cardiomyopathy

View Full Paper

Ask AI

Bookmark

Key result

Immunoadsorption therapy reduced plasma B-type natriuretic peptide concentrations by 50% in patients with refractory heart failure due to dilated cardiomyopathy.

Why the study?

Does immunoadsorption therapy improve cardiac function and reduce BNP in patients with refractory heart failure due to dilated cardiomyopathy?

Population

10 patients with refractory heart failure as a result of dilated cardiomyopathy (DCM)

Design

Review

Follow-up

up to 6 months

Authors

TYTsutomu YoshikawaHeart Failure & Transplant ABAkiyasu BabaTokai University YNYuji NagatomoHeart Failure / Cardiomyopathy

Discussion

Member takes

Implication

May support BNP reduction in refractory DCM-HF; hypothesis-generating and leaves open clinical adoption pending RCTs.

Structured PICO

Does immunoadsorption therapy improve cardiac function and reduce BNP in patients with refractory heart failure due to dilated cardiomyopathy?

Population

10 patients with refractory heart failure as a result of dilated cardiomyopathy (DCM)

Intervention

Immunoadsorption therapy using a tryptophan column to remove autoantibodies (3 to 5 sessions)

Outcome

Plasma B-type natriuretic peptide (BNP) concentration and left ventricular ejection fraction (LVEF)surrogate

Autoantibodies play a pivotal role in the pathophysiology of dilated cardiomyopathy, and their removal via immunoadsorption therapy may offer a novel treatment for refractory heart failure.

Limitations

Evaluation of the chronic effect of immunoadsorption therapy on cardiac function has not been established
Long-term effects on cardiac function, morbidity, and mortality await further investigation
Effective screening methods to identify responders to immunoadsorption therapy need to be developed
Evaluation of the chronic effect of this therapy on cardiac function has not been established
Long-term effects on cardiac function, morbidity and mortality await further investigation
Need to develop effective screening methods to identify responders

Cite This Study

Yoshikawa et al. (2009) conducted a review in Dilated Cardiomyopathy. Immunoadsorption therapy was evaluated. Immunoadsorption therapy reduced plasma B-type natriuretic peptide concentrations by 50% in patients with refractory heart failure due to dilated cardiomyopathy.

synapsesocial.com/papers/6a092ea3266340834eb630c1 https://doi.org/10.1253/circj.cj-08-1151

Topics

Heart failure HFrEF treatment Atrial fibrillation Persistent AF management Myocarditis

View Full Paper

Ask AI

Bookmark

Autoimmune Mechanisms Underlying Dilated Cardiomyopathy

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Topics

Autoimmune Mechanisms Underlying Dilated Cardiomyopathy

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider